Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.57 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | CES1 | P23141 | 1/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | HTR3A | P46098 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL100775 | 1.00 | HIF1A (0.57) | HIF1ACTBP2LMNASMN1; SMN2KDM1A | |
| SCHEMBL100774 | 1.00 | HIF1A (0.57) | HIF1ACTBP2LMNASMN1; SMN2KDM1A | |
| SCHEMBL17730475 | 0.92 | SLC22A2 (0.53) | HIF1ACTBP2LMNASMN1; SMN2KDM1A | |
| SCHEMBL21096339 | 0.87 | LMNA (0.53) | HIF1ACTBP2LMNASMN1; SMN2KDM1A | |
| SCHEMBL28911258 | 0.87 | LMNA (0.53) | HIF1ACTBP2LMNASMN1; SMN2KDM1A | |
| SCHEMBL5955216 | 0.81 | HIF1A (0.57) | HIF1ACTBP2LMNASMN1; SMN2CES2 | |
| SCHEMBL5955218 | 0.81 | HIF1A (0.57) | HIF1ACTBP2LMNASMN1; SMN2CES2 | |
| SCHEMBL10397502 | 0.80 | NPC1 (0.57) | ALDH1A1 | |
| SCHEMBL10397503 | 0.80 | NPC1 (0.57) | ALDH1A1 | |
| SCHEMBL21824482 | 0.80 | MEN1 (0.44) | HIF1ALMNASMN1; SMN2ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388601-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2025-12-25 | — | — | US | disclosed |
| US-12358928-B2 | Compounds, compositions and methods | DENALI THERAPEUTICS INC. (US) | 2025-07-15 | — | — | US | disclosed |
| CN-118994191-A | Inhibitors of receptor interacting protein kinase 1 | 戴纳立制药公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-118994190-A | Inhibitors of receptor interacting protein kinase 1 | 戴纳立制药公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-114437105-B | Inhibitors of receptor interacting protein kinase 1 | 戴纳立制药公司 | 2024-10-11 | — | — | CN | disclosed |
| US-20240150376-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2024-05-09 | — | — | US | disclosed |
| US-11795196-B2 | Mitochondria-targeting peptides | STEALTH BIOTHERAPEUTICS INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11795196-B2 | Mitochondria-targeting peptides | STEALTH BIOTHERAPEUTICS INC. (US) | 2023-10-24 | — | — | US | disclosed |
| EP-4218785-A2 | MITOCHONDRIA-TARGETING PEPTIDES | Stealth BioTherapeutics Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20230146515-A1 | MITOCHONDRIA-TARGETING PEPTIDES | STEALTH BIOTHERAPEUTICS INC. | 2023-05-11 | — | — | US | disclosed |
| US-7462624-B2 | Purinone derivatives as HM74a agonists | INCYTE CORPORATION (US) | 2008-12-09 | — | — | US | disclosed |
| US-20080139505-A1 | Potentiators Of Glutamate Receptors | ARRAY BIOPHARMA, INC. | 2008-06-12 | — | — | US | disclosed |
| US-20080045554-A1 | hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors; avoiding adverse effects such as hepatotoxicity and cutaneous flushing; low dosage; 2-bromo-8-methyl-4-pentyl-1,4-dihydro-5H-[1,2,4]triazolo[5,1-i]purin-5-one; to treat cardiovascular disorders | INCYTE CORPORATION (US) | 2008-02-21 | — | — | US | disclosed |
| US-20080045555-A1 | PURINONE DERIVATIVES AS HM74A AGONISTS | INCYTE CORPORATION (US) | 2008-02-21 | — | — | US | disclosed |
| US-20070293515-A1 | 1,3-Disubstituted Heteroaryl Nmda/Nr2b Antagonists | MERCK SHARP & DOHME CORP. | 2007-12-20 | — | — | US | disclosed |
| US-20070293515-A1 | 1,3-Disubstituted Heteroaryl Nmda/Nr2b Antagonists | MERCK SHARP & DOHME CORP. | 2007-12-20 | — | — | US | disclosed |
| US-20070293515-A1 | 1,3-Disubstituted Heteroaryl Nmda/Nr2b Antagonists | MERCK SHARP & DOHME CORP. | 2007-12-20 | — | — | US | disclosed |
| US-7217714-B1 | CCR5 modulators | AGOURON PHARMACEUTICALS, INC. (US) | 2007-05-15 | — | — | US | disclosed |
| US-7217714-B1 | CCR5 modulators | AGOURON PHARMACEUTICALS, INC. (US) | 2007-05-15 | — | — | US | disclosed |
| WO-2006017409-A2 | 1,3-DISUBSTITUTED HETEROARYL NMDA/NR2B ANTAGONISTS | MERCK & CO., INC. (US) | 2006-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139505-A1 | Potentiators Of Glutamate Receptors | GRM1, GRIN1, GRM2 | HIF1A 1312/4885CTBP2 3078/4885LMNA 4832/4885 |
| US-20070293515-A1 | 1,3-Disubstituted Heteroaryl Nmda/Nr2b Antagonists | GRIN2B, GRIN2A, GRIN1 | HIF1A 862/4885CTBP2 3516/4885LMNA 4298/4885 |
| US-20250388601-A1 | Compounds, Compositions and Methods | AURKC, WEE2, ERBB2 | HIF1A 2807/4885CTBP2 3381/4885LMNA 581/4885 |
| US-20240150376-A1 | Compounds, Compositions and Methods | PIK3CA, PLK1, PIK3CB | HIF1A 3501/4885CTBP2 2719/4885LMNA 1620/4885 |
| US-20080045555-A1 | PURINONE DERIVATIVES AS HM74A AGONISTS | GPR84, P2RY1, ADRA1A | HIF1A 1714/4885CTBP2 4141/4885LMNA 2374/4885 |
| US-20080045554-A1 | hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors; avoiding adverse effects such as hepatotoxicity and cutaneous flushing; low dosage; 2-bromo-8-methyl-4-pentyl-1,4-dihydro-5H-[1,2,4]triazolo[5,1-i]purin-5-one; to treat cardiovascular disorders | HMGCR, LDLR, GPBAR1 | HIF1A 3139/4885CTBP2 4575/4885LMNA 2063/4885 |
| US-12358928-B2 | Compounds, compositions and methods | PIK3CA, PLK1, PIK3CB | HIF1A 3501/4885CTBP2 2719/4885LMNA 1620/4885 |
| US-11795196-B2 | Mitochondria-targeting peptides | HSPE1, TFAM, TNNI3 | HIF1A 644/4885CTBP2 1164/4885LMNA 2107/4885 |
| US-20230146515-A1 | MITOCHONDRIA-TARGETING PEPTIDES | HSPE1, TFAM, TNNI3 | HIF1A 644/4885CTBP2 1164/4885LMNA 2107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.